MMP-2 Polyclonal Antibody

catalytic activity:Cleavage of gelatin type I and collagen types IV, V, VII, X. Cleaves the collagen-like sequence Pro-Gln-Gly-|-Ile-Ala-Gly-Gln.,cofactor:Binds 2 zinc ions per subunit.,cofactor:Binds 4 calcium ions per subunit.,disease:Defects in MMP2 are the cause of Torg-Winchester syndrome [MIM:259600]; also called multicentric osteolysis nodulosis and arthropathy (MONA). Torg-Winchester syndrome is an autosomal recessive osteolysis syndrome. It is severe with generalized osteolysis and osteopenia. Subcutaneous nodules are usually absent. Torg-Winchester syndrome has been associated with a number of additional features including coarse face, corneal opacities, patches of thickened, hyperpigmented skin, hypertrichosis and gum hypertrophy. However, these features are not always present and have occasionally been observed in other osteolysis syndromes.,domain:The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.,enzyme regulation:Inhibited by histatin-3 1/24 (histatin-5).,function:In addition to gelatin and collagens, it cleaves KiSS1 at a Gly-|-Leu bond.,PTM:The propeptide is processed by MMP14 (MT-MMP1) and MMP16 (MT-MMP3).,similarity:Belongs to the peptidase M10A family.,similarity:Contains 3 fibronectin type-II domains.,similarity:Contains 4 hemopexin-like domains.,subunit:Ligand for integrin alpha-V/beta-3.,tissue specificity:Produced by normal skin fibroblasts.,